Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00372905 · ClinicalTrials.gov registry record · Phase 1
Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular Lymphoma
A Phase 1 study, sponsored by Northwestern University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT00372905 is a Phase 1 study that was terminated before completion, run by Northwestern University. The registered enrollment target is 18 participants.
The verdict
NCT00372905, a Phase 1 study, was terminated before completion, sponsored by Northwestern University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Radiolabeled monoclonal antibodies, such as yttrium Y 90 ibritumomab tiuxetan, can find cancer cells and carry cancer-killing substances to them without harming normal cells. Giving bortezomib together with rituximab and yttrium Y 90 ibritumomab tiuxetan may kill more cancer cells. This phase I/II trial is studying the side effects and best dose of bortezomib when given together with rituximab and yttrium Y 90 ibritumomab tiuxetan and to see how well they work in treating patients with relapsed or refractory follicular non-Hodgkin's lymphoma.
Interventions
- DRUG rituximab
- DRUG bortezomib
- DRUG Ibritumomab tiuxetan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2007-07-24 |
| Est. Completion | 2013-07-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00372905
The ClinicalTrials.gov registry entry for NCT00372905 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which rituximab is the first listed.
NCT00372905 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00372905 about?
NCT00372905 is a clinical study titled "Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular Lymphoma". Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry ...
What is the current status of trial NCT00372905?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2007-07-24. Estimated completion is 2013-07-08.
What interventions are being tested in trial NCT00372905?
The interventions under investigation include: rituximab (DRUG), bortezomib (DRUG), Ibritumomab tiuxetan (DRUG).
Who is sponsoring clinical trial NCT00372905?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.